Vigencell announced positive top‑line results from a Phase II study of VT‑EBV‑N, an antigen‑specific killer T‑cell therapy targeting Epstein‑Barr virus‑associated natural killer T‑cell lymphoma (NKTCL). The program met its primary endpoint and the company plans to seek conditional approval in South Korea based on the data. Vigencell described VT‑EBV‑N as the first trial‑proven NKTCL‑targeting cell therapy to show efficacy in clinical testing. The company intends to move rapidly through regulatory processes and pursue commercialization domestically and internationally, citing the unmet need in this aggressive lymphoma subtype.